BKYI
BIO KEY INTERNATIONAL INC
Next earnings Aug 11, 2026 · consensus $-0.82 EPS, $2.24M rev
Last earnings +0.5% on 2026-05-18
$4.60
▲ 0.00%$4.60▼ -44.58%
over 1Y
L $3.46EODHDH $10.30
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.0%
1W+17.9%
1M+1.1%
3M-19.3%
YTD-22.0%
1Y-44.6%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Conservative balance sheet (liabilities/equity 0.63x); but revenue fell -14.3% YoY.
Revenue (FY2025) $5.94M · FY2025
BIO KEY INTERNATIONAL INC shows $5.94M in FY2025 revenue (-14.3% YoY), a -120.6% net margin, and -140.2% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $5.11M | $7.02M | $7.75M | $6.93M | $5.94M |
| Gross profit | $3.44M | $4.58M | $1.43M | $5.64M | $4.56M |
| Operating income | -$4.94M | -$9.92M | -$8.83M | -$4.01M | -$6.83M |
| Net income | -$5.07M | -$11.9M | -$8.52M | -$4.30M | -$7.16M |
| Diluted EPS | -$0.65 | — | — | — | — |
| Net margin | -99.0% | -169.7% | -109.9% | -62.1% | -120.6% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.48M
EV / EBITDA—
EV / Sales0.4
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-143.4%
FCF yield-93.8%
Quality & risk
ROIC (est.)-102.0%
Free cash flow-$4.68M
Total debt$183K
Net cash$2.51M
Altman Z-Score-23.86 distress
Piotroski F-Score4/9
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY-81.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRed flag in recent filings — restated periodic report (2026-06-15). Worth a closer look.
Recent filings
all on EDGAR ↗10-QPeriod ending 2026-03-312026-06-22open ↗10-K/APeriod ending 2025-12-312026-06-15open ↗10-KPeriod ending 2025-12-312026-06-12open ↗8-KPeriod ending 2026-06-052026-06-10open ↗NT 10-QPeriod ending 2026-03-312026-05-18open ↗8-KPeriod ending 2026-05-182026-05-18open ↗8-KPeriod ending 2026-05-062026-05-12open ↗8-KPeriod ending 2026-04-282026-04-29open ↗8-KPeriod ending 2026-04-202026-04-24open ↗8-KPeriod ending 2026-04-162026-04-22open ↗8-KPeriod ending 2026-04-162026-04-20open ↗NT 10-KPeriod ending 2025-12-312026-03-31open ↗
Frequently asked
- Is BIO KEY INTERNATIONAL INC (BKYI) a buy?
- BKYI currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.63x); but revenue fell -14.3% YoY.
- What is BIO KEY INTERNATIONAL INC's quality score?
- BKYI scores 46.764705882352935/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001019034, latest 10-Q filed 2026-06-22) · EODHD · as of 6/26/2026, 4:32:18 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.